Ukko

Ukko's mission is to improve the lives of people with food allergies and sensitivities. Ukko uses immunology, machine learning, and protein engineering to make measurably better and safer proteins for use in food and therapeutics. Ukko does this by designing and controlling the molecular interactions between allergen proteins and the immune system. Ukko's technology uses samples from patients and machine learning to guide the engineering of superior proteins that can be incorporated into food products and therapeutics. These proteins maintain or improve beneficial properties (taste, nutritional value, yield, and physicochemical and mechanical properties) but do not trigger an immune response. Ukko's initial product pipeline includes celiac-safe gluten proteins, allergy-safe and therapeutic peanut proteins, as well as a pipeline of additional allergen proteins.

Ukko has raised $47.7M in total funding across 3 rounds. The company is currently at the A stage. Key investors include Sanara Capital, Leaps by Bayer, Khosla Ventures.

Ukko was founded in 2016 by Yanay Ofran (Co-founder & Chairman), Anat Binur (Co-founder & CEO).

Ukko operates in Agriculture & Food Technologies, Food Tech, Novel Food & Ingredients, with core technologies in Artificial Intelligence, Biologicals. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals, Agriculture & Food, Processed Foods, Ingredients.

Ukko is based in HaMada Street 12, Rehovot, Israel, Center District. The company also has offices abroad.